Jubilant Organosys sells $200 million CB while pondering possible acquisition

Issue marks seventh CB from an Indian pharmaceutical company since December; conversion premiums still high.

Jubilant Organosys yesterday April 25 became the latest in growing line-up of Indian pharmaceutical companies to raise fresh capital from the sale of five-year convertible bonds as the industry prepares for another wave of expansion.

Jubilant, which also produces various chemicals and adhesives, raised $200 million from a bought deal arranged by JPMorgan which offered the bonds on to investors at fixed terms which included a 50% conversion premium. It was the fourth time since May 2004 that the...

To continue reading, please login or register for free

Click for more on: convertible | pharmaceuticals | drugs | jpmorgan

Print Edition

FinanceAsia Print Edition

CONFERENCES